Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection.

@article{Re2017RiskOL,
  title={Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection.},
  author={Vincent Lo Re and Bret Zeldow and Michael J. Kallan and Janet P. Tate and Dena M. Carbonari and Sean Hennessy and Jay R. Kostman and J K Lim and Matthew Bidwell Goetz and Robert Gross and Amy C. Justice and Jason Roy},
  journal={Pharmacoepidemiology and drug safety},
  year={2017},
  volume={26 10},
  pages={1172-1181}
}
PURPOSE Among patients dually infected with human immunodeficiency virus (HIV) and chronic hepatitis C virus (HCV), use of antiretroviral therapy (ART) containing mitochondrial toxic nucleoside reverse transcriptase inhibitors (mtNRTIs) might induce chronic hepatic injury, which could accelerate HCV-associated liver fibrosis and increase the risk of hepatic… CONTINUE READING